RxDoctor Payments Data

Jennifer Cannon, APRN

Family · Canton, CTNPI 1528461647

Payments from drug & device makers

$4,436in general payments, 2019–2025

Across 305 payments — averaging $14.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$768
  • Gilead$191
  • Johnson & Johnson$189
  • Novo Nordisk$135
  • Indivior Inc.$134
  • plus $690 from 13 others

What the payments were for

  • Food & beverage$4,436100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,436 in reported general payments places this provider in the 90th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$10,392
Medicare patients
16
Services billed
167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SublocadeBuprenorphine48$100,405
VraylarCariprazine Hcl21$46,266
MounjaroTirzepatide31$39,538
LinzessLinaclotide14$21,252
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$4,178
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine60$2,426
Rosuvastatin Calcium44$929
Gabapentin33$713
Methocarbamol18$709
Buspirone Hcl32$620
Omega-3 Acid Ethyl Esters12$600
Pregabalin14$584
Alprazolam25$564
Omeprazole27$503
Lamotrigine33$481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Sublocade$134$100,40548 claims
AbbVieVraylar, Linzess$2,330$67,51835 claims
Lilly USA, LLCMounjaro$54$39,53831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,596 family providers in Connecticut.

Other family in Canton

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →